Rishabh Jain, Medical Oncologist at AIIMS, shared a post on X about a paper by Joe-Elie Salem et al. published in the European Heart Journal:
“Rare but deadly: Immune checkpoint inhibitors (ICI) can trigger myocarditis and myositis.
- French nationwide cohort (n=172,363) reports:
- Incidence: 0.7–0.9% at 6 months
- Highest in thymic ca (7.1%)
- Major risk factors: thymic disorders, myasthenia, melanoma, combo ICI, age >85 y
- 1-month fatality: ~20%
- Take-home: ICI myotoxicity = strongest predictor of early mortality (HR 3.5 at 30d).
Salem JE, et al. Eur Heart J. 2025.”
Title: Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study
Authors: Joe-Elie Salem, Aya Ajrouche, Antoine Rozes, Sandrine Pinto, Yann De Rycke, Florence Tubach
You can read the Full Article in the European Heart Journal.
More posts featuring Rishabh Jain.
